These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 11294511

  • 1. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
    van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE.
    Ther Drug Monit; 2001 Apr; 23(2):119-28. PubMed ID: 11294511
    [Abstract] [Full Text] [Related]

  • 2. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 3. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.
    Park JM, Lake KD, Cibrik DM.
    Ther Drug Monit; 2008 Oct; 30(5):591-6. PubMed ID: 18708992
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function.
    Barten MJ, Shipkova M, Bartsch P, Dhein S, Streit F, Tarnok A, Armstrong VW, Mohr FW, Oellerich M, Gummert JF.
    Ther Drug Monit; 2005 Apr; 27(2):123-31. PubMed ID: 15795640
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.
    Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T.
    Am J Transplant; 2005 May; 5(5):987-94. PubMed ID: 15816878
    [Abstract] [Full Text] [Related]

  • 6. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 8. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication.
    Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM.
    Ther Drug Monit; 2002 Oct; 24(5):598-606. PubMed ID: 12352931
    [Abstract] [Full Text] [Related]

  • 10. Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.
    Noreikaitė A, Saint-Marcoux F, Marquet P, Kaduševičius E, Stankevičius E.
    Medicine (Baltimore); 2017 Mar; 96(13):e6469. PubMed ID: 28353583
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE, Tett SE.
    Clin Pharmacokinet; 2007 Mar; 46(1):13-58. PubMed ID: 17201457
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 13. Influence of metal cations on plasma trough concentration of mycophenolic Acid and its glucuronide in tacrolimus-treated and cyclosporine-treated kidney transplant recipients.
    Naito T, Mino Y, Otsuka A, Ushiyama T, Ozono S, Kagawa Y, Kawakami J.
    Biol Pharm Bull; 2008 Jun; 31(6):1292-6. PubMed ID: 18520072
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE, Nicholls AJ, Kamm BR.
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [Abstract] [Full Text] [Related]

  • 15. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats.
    Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T.
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1029-35. PubMed ID: 14978191
    [Abstract] [Full Text] [Related]

  • 17. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients.
    Barten MJ, Rahmel A, Garbade J, Bold A, Bittner HB, Dhein S, Mohr FW, Gummert JF.
    Transplant Proc; 2005 Dec; 37(10):4532-4. PubMed ID: 16387162
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 20. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
    Morissette P, Albert C, Busque S, St-Louis G, Vinet B.
    Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.